Sinopharm Group (HKG:1099) has renewed five existing agreements with its controlling shareholder, China National Pharmaceutical Group Corp., for three years ahead of their expiry, according to a Monday bourse filing.
The company said it will continue procuring and selling CNPGC's products, as well as utilizing its EPC general contracting, factoring, and financial services from 2027 through 2029.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments